Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	2.21B -30.9%
Revenue (ttm)	412.51M -7.6%
Net Income	37.59M +8.8%
EPS	0.42 +9.9%
Shares Out	88.59M
PE Ratio	59.71
Forward PE	n/a
Dividend	0.22 (0.90%)
Ex-Dividend Date	May 29, 2026

Volume	1,555,199
Open	24.60
Previous Close	24.55
Day's Range	24.58 - 25.20
52-Week Range	21.78 - 39.02
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 540
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2025, SHE:301258's revenue was 432.73 million, an increase of 0.76% compared to the previous year's 429.47 million. Earnings were 64.29 million, an increase of 291.89%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 4, 2026

Data Sources Report a data error